JP4772688B2 - メタドヘリンポリペプチドとそのコード核酸及び使用方法 - Google Patents

メタドヘリンポリペプチドとそのコード核酸及び使用方法 Download PDF

Info

Publication number
JP4772688B2
JP4772688B2 JP2006539793A JP2006539793A JP4772688B2 JP 4772688 B2 JP4772688 B2 JP 4772688B2 JP 2006539793 A JP2006539793 A JP 2006539793A JP 2006539793 A JP2006539793 A JP 2006539793A JP 4772688 B2 JP4772688 B2 JP 4772688B2
Authority
JP
Japan
Prior art keywords
metadherin
lung
antibody
cells
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006539793A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007514655A5 (https=
JP2007514655A (ja
Inventor
ルースラーティ，エルッキ
エム． ブラウン，ダレン
Original Assignee
ザ バーナム インスティチュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ バーナム インスティチュート filed Critical ザ バーナム インスティチュート
Publication of JP2007514655A publication Critical patent/JP2007514655A/ja
Publication of JP2007514655A5 publication Critical patent/JP2007514655A5/ja
Application granted granted Critical
Publication of JP4772688B2 publication Critical patent/JP4772688B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G01N2021/6439—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" with indicators, stains, dyes, tags, labels, marks
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/645—Specially adapted constructive features of fluorimeters
    • G01N21/648—Specially adapted constructive features of fluorimeters using evanescent coupling or surface plasmon coupling for the excitation of fluorescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Optics & Photonics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006539793A 2003-11-13 2004-11-10 メタドヘリンポリペプチドとそのコード核酸及び使用方法 Expired - Fee Related JP4772688B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51967503P 2003-11-13 2003-11-13
US60/519,675 2003-11-13
PCT/US2004/037471 WO2005050198A2 (en) 2003-11-13 2004-11-10 Metadherin polypeptides, encoding nucleic acids and methods of use

Publications (3)

Publication Number Publication Date
JP2007514655A JP2007514655A (ja) 2007-06-07
JP2007514655A5 JP2007514655A5 (https=) 2007-12-27
JP4772688B2 true JP4772688B2 (ja) 2011-09-14

Family

ID=34619368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539793A Expired - Fee Related JP4772688B2 (ja) 2003-11-13 2004-11-10 メタドヘリンポリペプチドとそのコード核酸及び使用方法

Country Status (4)

Country Link
US (2) US7560242B2 (https=)
EP (1) EP1695078A4 (https=)
JP (1) JP4772688B2 (https=)
WO (1) WO2005050198A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1742969A2 (en) * 2003-11-12 2007-01-17 OncoMab GmbH Methods of identifying neoplasm-specific antibodies and uses thereof
WO2005050198A2 (en) * 2003-11-13 2005-06-02 The Burnham Institute Metadherin polypeptides, encoding nucleic acids and methods of use
DE102007017061A1 (de) 2007-04-11 2008-10-16 Voith Patent Gmbh Verfahren zur Herstellung von Tissuepapier
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
AU2010315301B2 (en) 2009-11-06 2014-01-23 Hollister Incorporated Multi-layer film and ostomy product made therefrom
US9322051B2 (en) 2013-10-07 2016-04-26 General Electric Company Probing of biological samples
AU2015279834A1 (en) 2014-06-25 2016-12-22 The Trustees Of Princeton University Use of peptides that block metadherin-SND1 interaction as treatment for cancer
EP3791930A1 (en) * 2019-09-13 2021-03-17 Secarna Pharmaceuticals GmbH & Co. KG Inhibitor of metadherin expression

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056765A1 (en) * 1999-03-19 2000-09-28 Human Genome Sciences, Inc. 48 human secreted proteins
WO2003077875A2 (en) * 2002-03-15 2003-09-25 Incyte Corporation Proteins associated with growth, differentiation, and death
WO2004053075A2 (en) * 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496850A (en) * 1991-04-11 1996-03-05 Toray Industries, Inc. Antimetastasis agent of malignant tumors
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5552390A (en) * 1993-12-09 1996-09-03 The Board Of Regents Of The University Of Nebraska Phosphorothioate inhibitors of metastatic breast cancer
US6590076B1 (en) * 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
CA2478909A1 (en) * 2002-03-13 2003-09-25 Duane D. Miller Substituted tetrahydroisoquinoline compounds, methods of making, and their use
AU2003285490A1 (en) * 2002-04-29 2004-03-03 The Trustees Of Columbia University In The City Of New York Astrocyte modulated genes and uses thereof
WO2005050198A2 (en) * 2003-11-13 2005-06-02 The Burnham Institute Metadherin polypeptides, encoding nucleic acids and methods of use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000056765A1 (en) * 1999-03-19 2000-09-28 Human Genome Sciences, Inc. 48 human secreted proteins
WO2003077875A2 (en) * 2002-03-15 2003-09-25 Incyte Corporation Proteins associated with growth, differentiation, and death
WO2004053075A2 (en) * 2002-12-05 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to breast specific genes and proteins

Also Published As

Publication number Publication date
US20090221718A1 (en) 2009-09-03
WO2005050198A3 (en) 2005-07-07
EP1695078A2 (en) 2006-08-30
US8188051B2 (en) 2012-05-29
EP1695078A4 (en) 2007-07-11
WO2005050198A2 (en) 2005-06-02
US20050208057A1 (en) 2005-09-22
JP2007514655A (ja) 2007-06-07
US7560242B2 (en) 2009-07-14

Similar Documents

Publication Publication Date Title
US8188051B2 (en) Metadherin polypeptides, encoding nucleic acids and methods of use
EP1814909B1 (en) Use of aimp2dx2 for the diagnosis and treatment of cancer
JP5554925B2 (ja) ヒト非小細胞肺癌における転座及び変異体ｒｏｓキナーゼ
AU2011250588C1 (en) Method for the diagnosis of epithelial cancers by the detection of EpICD polypeptide
AU2011250588B2 (en) Method for the diagnosis of epithelial cancers by the detection of EpICD polypeptide
WO1999033963A1 (en) Metastatic cancer regulated gene
KR20150082278A (ko) 암 치료 및 진단의 타겟으로서 ly75
US20090196873A1 (en) Methods and compositions for treating diseases targeting CDCP1
JP2005510734A (ja) 上皮誘導性癌の診断および治療方法
KR20190072466A (ko) Pd-l1에 결합하는 펩타이드 및 이의 용도
EP2452948B1 (en) New tumor marker
CA2355870A1 (en) Reagents and methods useful for detecting diseases of the breast
JP2009142282A (ja) 癌性胸部細胞において差次的に発現された遺伝子産物およびその使用方法
ES2587055T3 (es) Una nueva molécula asociada a tumores humanos metastásicos, métodos para detectar tanto el gen activado como la proteína y para interferir con la expresión génica
US9581598B2 (en) Diagnosis and treatment of brain tumor
US20120195829A1 (en) Methods for identifying targeting domains and method and compositions comprising the same
ES3040185T3 (en) Use of bmmf1 rep protein as a biomarker for breast cancer
US6552164B1 (en) Reagents and methods useful for detecting diseases of the breast
US6379951B1 (en) Compounds for immunotherapy of breast cancer and methods for their use
WO2003066639A2 (en) Methods for identifying targeting domains and methods and compositions comprising the same
JP2014532408A (ja) ＵＳＰ２ａペプチドおよび抗体
US20100202964A1 (en) Organ Homing Genes of Cancer Metastases
US20040005646A1 (en) Use of the S2-6 gene product as a diagnostic marker for cancer detection
US20060035239A1 (en) Method and compositions for treating diseases targeting CD51
US8507213B1 (en) Methods and compositions for treating diseases targeting maba

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110502

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110531

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110622

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140701

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees